Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2020

Open Access 01-12-2020 | Lung Cancer | Letter to the Editor

Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection

Authors: Qi Kong, Zhiguang Xiang, Yue Wu, Yu Gu, Jianguo Guo, Fei Geng

Published in: Molecular Cancer | Issue 1/2020

Login to get access

Abstract

Recent studies have reported that COVID-19 patients with lung cancer have a higher risk of severe events than patients without cancer. In this study, we investigated the gene expression of angiotensin I-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) with prognosis in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Lung cancer patients in each age stage, subtype, and pathological stage are susceptible to SARS-CoV-2 infection, except for the primitive subtype of LUSC. LUAD patients are more susceptible to SARS-CoV-2 infection than LUSC patients. The findings are unanimous on tissue expression in gene and protein levels.
Literature
1.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.CrossRef
2.
3.
Ringnér M, Jönsson G, Staaf J. Prognostic and chemotherapy predictive value of gene-expression phenotypes in primary lung adenocarcinoma. Clin Cancer Res. 2016;22(1):218–29.CrossRef
4.
Wu D, Pang Y, Wilkerson MD, et al. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. Br J Cancer. 2013;109(6):1599–608.CrossRef
5.
6.
Yang XH, Deng W, Tong Z, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med. 2007;57(5):450–9.PubMed
7.
Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al. TMPRSS2 contributes to virus spread and immunopathology in the Airways of Murine Models after coronavirus infection. J Virol. 2019;93(6):e01815–8.PubMedPubMedCentral
8.
Yoshikawa T, Hill TE, Yoshikawa N, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS One. 2010;5(1):e8729.CrossRef
Metadata
Title
Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection
Authors
Qi Kong
Zhiguang Xiang
Yue Wu
Yu Gu
Jianguo Guo
Fei Geng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2020
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-020-01209-2

Other articles of this Issue 1/2020

Molecular Cancer 1/2020 Go to the issue

Review

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review

Letter to the Editor

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer

Research

Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA

Letter to the Editor

Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies

Review

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Correction

Correction to: CircDLST promotes the tumorigenesis and metastasis of gastric cancer by sponging miR-502-5p and activating the NRAS/MEK1/ERK1/2 signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits